rate of all specific postoperative complications newly observed during a period of 30 days after surgery in those study patients who received at least the first 3 doses of catumaxomab 30 days after last catumaxomab administration [clinicaltrials_resource:577c466d8c39e7088786d4550826dd89]
Patients will get first the chemotherapeutic regimen (Epirubicin, Cisplatin and Capecitabine or 5-Fluorouracil) consisting of three 21-day cycles, starting on the weeks 1, 4 and 7. Four weeks after CTx the D2 surgery will take place. Treatment with catumaxomab will consist of an initial dose of 10µg given intraoperatively as in intraperitoneal bolus and of four postoperative ascending doses.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
rate of all specific postoperative complications newly observed during a period of 30 days after surgery in those study patients who received at least the first 3 doses of catumaxomab 30 days after last catumaxomab administration [clinicaltrials_resource:577c466d8c39e7088786d4550826dd89]
Patients will get first the chemotherapeutic regimen (Epirubicin, Cisplatin and Capecitabine or 5-Fluorouracil) consisting of three 21-day cycles, starting on the weeks 1, 4 and 7. Four weeks after CTx the D2 surgery will take place. Treatment with catumaxomab will consist of an initial dose of 10µg given intraoperatively as in intraperitoneal bolus and of four postoperative ascending doses.
Bio2RDF identifier
577c466d8c39e7088786d4550826dd89
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:577c466d8c39e7088786d4550826dd89
measure [clinicaltrials_vocabulary:measure]
rate of all specific postopera ...... first 3 doses of catumaxomab
time frame [clinicaltrials_vocabulary:time-frame]
30 days after last catumaxomab administration
description
Patients will get first the ch ...... postoperative ascending doses.
identifier
clinicaltrials_resource:577c466d8c39e7088786d4550826dd89
title
rate of all specific postopera ...... ast catumaxomab administration
@en
type
label
rate of all specific postopera ...... c466d8c39e7088786d4550826dd89]
@en